REPORT FROM THE EUROPEAN CHARCOT FOUNDATION ANNUAL MEETING – BAVENO, ITALY, NOVEMBER 28-30, 2013 – The optimal strategy for managing patients with an inadequate response to an initial disease-modifying therapy (DMT) was the focus of discussion at a session of the ECF annual meeting and two somewhat different approaches were presented.